Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Asmussen, K. H.
Right arrow Articles by Bowman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Asmussen, K. H.
Right arrow Articles by Bowman, S. J.
Related Collections
Right arrow Sjogren's Syndrome
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1085-1088
© 2001 British Society for Rheumatology

Editorials

Outcome measures in Sjögren's syndrome

K. H. Asmussen and S. J. Bowman1,

Clinic for Orthopaedic Medicine and Rehabilitation, Rigshospitalet, Copenhagen University Hospital 9 Blegdamsvej, DK-2100 Copenhangen, Denmark and
1 Rheumatology Departments University of Birmingham and Birmingham Heartland Hospital, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Sjögren's syndrome (SS) is a systemic autoimmune disorder characterized by chronic focal lymphocytic inflammation of exocrine tissues leading to glandular dysfunction, in particular the diagnostic features of dry eyes and dry mouth [1]. SS may exist as a primary disorder or can be associated with other autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and progressive systemic sclerosis. The key clinical manifestations of SS are derived from the ocular and oral components as well as from musculoskeletal involvement and fatigue. The ‘systemic’ component of SS relates to B-cell hyperactivity and disease manifestations from internal organs, the integument and the nervous and haematopoietic systems. Apart from a significantly increased incidence of malignant lymphomas in these patients, systemic features are in general mild or subclinical as opposed to the prominent sicca features [2].

SS is regarded as a chronic, albeit treatable, disease. Although curative therapy . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?